This episode of the Endocrine Outlook features a conversation with Juan Frias, MD, medical director of the National Research Institute. Frias is also the principal investigator of the SURPASS-2 trial which examined Eli Lilly’s Dual GLP1/GIP agonist tirzepatide against 1mg semaglutide for glucose control and weight loss in patients with diabetes.